Lyell-Immunopharma on Bioeconhttps://en.bioecon.ru/companies/lyell-immunopharma/Recent content in Lyell-Immunopharma on BioeconHugoen-USSat, 11 Jul 2026 13:30:18 +0700TCR therapy (T-cell receptor engineered T cells)https://en.bioecon.ru/technology/tcr-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/tcr-therapy/Patient T cells are engineered with a high-affinity T-cell receptor (TCR) that recognises a peptide-MHC complex inside a solid-tumour cell — an approved one-time therapy reaching tumour targets CAR-T cannot, led by Adaptimmune’s Tecelra and Immunocore’s Kimmtrak, with a deeper pipeline advancing MAGE-A4, NY-ESO-1, gp100 and PRAME targets.